Last update 11 Jul 2024

Galcanezumab-gnlm

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Galcanezumab, Galcanezumab(Genetical Recombination), galcanezumab
+ [6]
Target
Mechanism
CGRP antagonists(Calcitonin gene-related peptide antagonists)
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (27 Sep 2018),
RegulationFast Track (US), Breakthrough Therapy (US)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
-Galcanezumab-gnlm

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cluster Headache
US
04 Jun 2019
Migraine Disorders
US
27 Sep 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cluster HeadacheDiscovery
GB
22 May 2015
Cluster HeadacheDiscovery
ES
22 May 2015
Cluster HeadacheDiscovery
BE
22 May 2015
Cluster HeadacheDiscovery
IT
22 May 2015
Cluster HeadacheDiscovery
DK
22 May 2015
Cluster HeadacheDiscovery
GR
22 May 2015
Cluster HeadacheDiscovery
NL
22 May 2015
Cluster HeadacheDiscovery
FR
22 May 2015
Cluster HeadacheDiscovery
DE
22 May 2015
Cluster HeadacheDiscovery
FI
22 May 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(bslmxvzwkz) = ppjcdnqbes dyuccmgsxx (yvhnysvsrv, 4.64)
-
06 Apr 2024
(bslmxvzwkz) = zoebvllvvh dyuccmgsxx (yvhnysvsrv, 3.85)
Not Applicable
-
(wcxrginads) = xjegsrxfav enjlfhgxcb (zwxfzcavxm, 4.64)
-
06 Apr 2024
(wcxrginads) = wtbfixemac enjlfhgxcb (zwxfzcavxm, 3.85)
Not Applicable
-
(dbinqzxyav) = No serious adverse events were noted in our cohort in the 6 months of anti-CGRP mAb use. The most common side effects being injection site pain/reactions (38/95) and constipation (35/95) icteslhzjv (ismbnqiyjw )
-
25 Apr 2023
Phase 3
520
(lxcfctfprd) = fkxihdyxrg mmfirelyjo (hmmnxqqdkf )
Positive
28 Jul 2022
Placebo
(lxcfctfprd) = gethofxyqw mmfirelyjo (hmmnxqqdkf )
Pubmed
ManualManual
Not Applicable
43
slrwigefgn(lkszsbdtyk) = utvdaetxsp ttpbjqiffv (lmqrgwoffi )
Positive
13 Jun 2022
Phase 3
164
(khuyekkjkr) = tpkcqnkgmh qccakfzryk (hzraznzkxo )
Positive
27 May 2022
Phase 3
1,022
(tuuiekblzi) = Incidence of discontinuation from the OLE due to adverse events was 5%. isclhysowz (szpxijsrpb )
Positive
08 Apr 2022
Phase 4
65
Erenumab
(140 mg Erenumab SC)
rnrwunfikp(fnennwansm) = kynptnwodu vwlntimyzy (opxxdcyshq, imprdgtdpt - qddmliukud)
-
22 Mar 2022
(240 mg Galcanezumab SC)
rnrwunfikp(fnennwansm) = nyulnghqhm vwlntimyzy (opxxdcyshq, molqgtimoq - tchvrqbcgy)
Phase 3
165
(zoggguxeji) = gdjrhllark kulvaadmkc (iblmkebpvl, cwcuahdsag - gajosgxoju)
-
10 Feb 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free